- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
SGLT2 inhibitors have similar fracture risk as other antidiabetics in postmenopausal women with diabetes: JAMA
South Korea: A claims-based study involving two independent Korean cohorts revealed that SGLT2 inhibitors are associated with a lower or similar risk of fracture versus incretin-based antidiabetic agents in postmenopausal women with type 2 diabetes (T2D). The study findings were published in JAMA Network Open on September 26, 2023.
The researchers showed that new users of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) had a lower risk for incident fractures versus those started on a DPP-4 inhibitor (weighted HR 0.78). In the second cohort, the fracture risk with SGLT2 inhibitors versus GLP-1 receptor agonists was no different (weighted HR 0.92).
Postmenopausal women with T2D are known to be susceptible to fractures due to the interaction of increased blood glucose levels and estrogen deficiency. There is a lack of existing evidence in this high-risk population despite continued concerns of fractured risks tied to SGLT2 inhibitors. To fill this knowledge gap, Hwa Yeon Ko, Sungkyunkwan University, Suwon, South Korea, and colleagues aimed to assess fracture risk associated with SGLT2 inhibitors versus incretin-based drugs of GLP1RA (glucagon-like peptide 1 receptor agonists) and DPP4i (dipeptidyl-peptidase 4 inhibitors), separately in postmenopausal women with type 2 diabetes.
For this purpose, the researchers conducted an active-comparator, new-user cohort study using nationwide claims data from Korea from 2013 to 2020. It included postmenopausal individuals (aged ≥45 years) with type 2 diabetes.
The primary outcome of the study was calculated as overall fractures comprising humerus, hip, vertebral, and distal radius fractures. Follow-up of the patients was done from the day after drug initiation until drug discontinuation (90-day grace period), earliest of outcome occurrence, or switch, death, or end of the study period. Hazard ratios (HRs) were estimated using weighted Cox models after propensity score fine stratification.
The study led to the following findings:
- Among 37 530 (mean age, 60.6 years) and 332 004 (mean age, 60.6 years) new users of SGLT2i and DPP4i, respectively, a lower rate of incident overall fractures was presented with SGLT2i versus DPP4i (weighted HR, 0.78).
- Among 111 835 (mean age, 61.4 years) and 8177 (mean age, 61.1 years) new users of SGLT2i and GLP1RA, respectively, no association with an increased risk of overall fractures was presented with SGLT2i versus GLP1RA (weighted HR, 0.92).
- Results from several subgroup and sensitivity analyses presented consistent results from the main analysis.
"The findings suggest that the use of SGLT2 inhibitors was not tied to an increased risk of overall fractures among postmenopausal patients with T2D," the researchers wrote. "The result remained consistent regardless of the particular incretin-based drug as an active comparator."
"These findings indicate that SGLT2 inhibitor has either similar or lower fracture risks than incretin-based drugs even in a population at higher risk for fractures, providing reassurance to and helping health care professionals with their clinical decision-making," they concluded.
Reference:
Ko HY, Bea S, Jeong HE, et al. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes. JAMA Netw Open. 2023;6(9):e2335797. doi:10.1001/jamanetworkopen.2023.35797
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751